RxDoctor Payments Data

Alfred Schlorke, DO

Family Medicine · Nappanee, INNPI 1912979444

Payments from drug & device makers

$1,091in general payments, 2019–2025

Across 66 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$302
  • AbbVie$270
  • Novo Nordisk$119
  • Astellas Pharma US Inc$59
  • Lilly USA, LLC$43
  • Supernus Pharmaceuticals, Inc.$41
  • plus $258 from 12 others

What the payments were for

  • Food & beverage$1,091100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,091 in reported general payments places this provider in the 60th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$58,385
Medicare patients
146
Services billed
2,541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$171,128
OzempicSemaglutide63$79,120
EliquisApixaban61$54,223
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$37,498
JanuviaSitagliptin Phosphate32$35,503
TrulicityDulaglutide18$28,666
FarxigaDapagliflozin Propanediol19$22,689
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$12,298
TradjentaLinagliptin12$10,617
JardianceEmpagliflozin13$10,161
VyvanseLisdexamfetamine Dimesylate23$8,981
Breo ElliptaFluticasone/Vilanterol19$8,964
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$7,664
Humalog Kwikpen U-100Insulin Lispro11$7,525
MotegrityPrucalopride Succinate12$6,521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$119$79,12063 claims
PfizerEliquis$302$54,22361 claims
AstraZenecaFarxiga, Breztri Aerosphere$36$34,98733 claims
Lilly USA, LLCTrulicity$43$28,66618 claims
Boehringer IngelheimTradjenta, Jardiance$16$20,77825 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Motegrity$16$15,50235 claims
Johnson & JohnsonXarelto$24$5,89311 claims
AbbVieSynthroid$270$1,70117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Nappanee

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →